key: cord-0748737-p0k2u3ff
authors: Sisa, Ivan; Noblecilla, Estefania; Orozco, Fadya
title: Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs
date: 2021-02-19
journal: Lancet
DOI: 10.1016/s0140-6736(21)00357-3
sha: 7fad3a458dc1f33a0a96fd4a17d59dcd967e6549
doc_id: 748737
cord_uid: p0k2u3ff

nan

In January, 2021, our institutional review board approved an application for a phase 3, placebo-controlled COVID-19 trial using a protein-based platform in Ecuador. Here we share our experience and the rationale used to approve this protocol. The following are the justifying elements used in our judgment. First, we had to consider economic and logistical issues. A proposed strategy to evaluate COVID-19 vaccines after EUA is to run head-to-head randomised trials with non-inferiority designs. 1 Due to an international shortage of approved vaccines, it is not feasible to do this kind of design locally. This constraint is even worse for low-income and middle-income countries (LMICs), which have less capacity to negotiate and purchase vaccines than do high-income countries (appendix). For example, by Feb 12, 2021, Ecuador was able to acquire 8000 doses of the Pfizer-BioNTech vaccine; however, there is a lot of uncertainty as to when and how many doses we will receive throughout the year to continue our massive vaccination programme.

Second, there is room to claim clinical equipoise in COVID-19 vaccine trials. Although we acknowledge the rigorous development process and comprehensive evaluation that the two vaccines faced to be granted EUA, they are still not completely licensed medical products and are subject to long-term surveillance, especially for safety. The scientific literature shows examples of fully licensed vaccines that have had to be taken off the market due to safety concerns (eg, Rotavirus vaccine). 3 Third, some scientists and bioethicists argue that researchers doing clinical trials should treat participants as if they were patients. If that is the case, in the best of their clinical interests, it would be unethical to give the participants a placebo. 2 We disagree with this argument and recognise that the researcher's obligations differ among participants and patients. After our institutional review board assessed the risk-benefit profile of the new candidate vaccine and concluded that the benefits outweigh the potential risks, we concluded that use of proper informed consent would allow participants to enrol in the trial and accept some risks to collect socially valuable data. 2 Having multiple vaccine producers to overcome this global shortage scenario is morally and ethically imperative, especially for LMICs.

We declare no competing interests.

College of Health Sciences (IS, FO) and Institutional Review Board (EN), Universidad San Francisco de Quito, Quito 170901, Ecuador

Evaluating SARS-CoV-2 vaccines after Emergency Use Authorization or licensing of initial candidate vaccines

COVID-19 vaccine trial ethics once we have efficacious vaccines

Rotavirus vaccine withdrawal in the United States. The role of postmarketing surveillance

For more on the COVID-19 vaccines for EUA by the FDA see

See Online for appendix